FDA sets late 2024 decision deadline for Pfizer’s ‘pan-hemophilia’ drug: #ASH23

SAN DIEGO — The FDA is expected to decide whether to approve Pfizer’s hemophilia A and B antibody in the fourth quarter of 2024, the New York pharma announced Monday afternoon. An approval of marstacimab could kickstart Pfizer’s challenge to Roche’s blockbuster Hemlibra in hemophilia A and provide a first…
Click here to view original post